Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin

Rodríguez‐Galindo, Carlos; Wilson, Matthew W.; Haik, Barrett G.; Merchant, Thomas E.; Billups, Catherine A.; Shah, Nirali N.; Cain, Alvida M.; Langston, J. William; Lipson, Mindy; Kun, Larry E.; Pratt, Charles B.

doi:10.1200/jco.2003.09.103

Cited by 162 publications

(100 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The series showed that carboplatin and vincristine or even carboplatin alone may achieve good tumor control. 12,[26][27][28] This new study shows that deescalation, using vincristine instead of etoposide, seems not enough active to achieve satisfactory tumor control and eye preservation without EBRT. Furthermore, the very low risks of etoposide-induced secondary leukemia (at the doses we used, only for the initial two courses) should not defer physicians from its use in this indication.…”

Section: Discussionmentioning

confidence: 99%

Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy

Rouic

Aerts

Hajage

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose Intraocular retinoblastoma treatments often combine chemotherapy and focal treatments. A first prospective protocol of conservative treatments in our institution showed the efficacy of the use of two courses of chemoreduction with etoposide and carboplatin, followed by chemothermotherapy using carboplatin as a single agent and diode laser. In order to decrease the possible longterm toxicity of chemotherapy due to etoposide, a randomized neoadjuvant phase II protocol was conducted using vincristinecarboplatin vs etoposide-carboplatin. Patients and methods The study was proposed when initial tumor characteristics did not allow front-line local treatments. Patients included in this phase II noncomparative randomized study of neoadjuvant chemotherapy received vincristin-carboplatin (new arm) vs etoposide-carboplatin (our reference arm). They were subsequently treated by local treatments and chemothermotherapy. Primary end point was the need for secondary enucleation or external beam radiotherapy (EBRT) not exceeding 40% at 2 years. Results A total of 65 eyes in 55 children were included in the study (May 2004 to August 2009. Of these, 32 eyes (27 children) were treated in the arm etoposide-carboplatin and 33 eyes (28 children) in the arm vincristin-carboplatin. At 2 years after treatment, 23/33 (69.7%) eyes were treated and salvaged without EBRT or enucleation in the arm vincristin-carboplatin and 26/32 (81.2%) in the arm etoposide-carboplatin. Conclusion Even if the two treatment arms could be considered as sufficiently active according to the study decision rules, neoadjuvant chemotherapy by two cycles of vincristine-carboplatin followed by chemothermotherapy appear to offer less optimal local control than the etoposidecarboplatin combination.

show abstract

Section: Discussionmentioning

confidence: 99%

Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy

Rouic

Aerts

Hajage

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…Even when combined with focal therapies, the triple drug combination is ineffective in as many as 40% of bilateral retinoblastoma patients (7). Moreover, etoposide has been found to increase the incidence of secondary malignancies likely due to DNA damage caused by this topoisomerase II inhibitor.…”

mentioning

confidence: 99%

“…Chemotherapy combined with laser treatment and cryotherapy has improved the eye salvage rate for children with bilateral retinoblastoma and preserved vision for some patients (7). However, latestage bilateral retinoblastoma remains difficult to treat with this approach (7). In addition, one of the drugs used to treat retinoblastoma worldwide (etoposide) is believed to be responsible for an increase in acute myeloblastic leukemia as a secondary malignancy (8).…”

mentioning

confidence: 99%

“…Children with retinoblastoma in both eyes often undergo anticancer therapy to avoid bilateral enucleation and blindness. Chemotherapy combined with laser treatment and cryotherapy has improved the eye salvage rate for children with bilateral retinoblastoma and preserved vision for some patients (7). However, latestage bilateral retinoblastoma remains difficult to treat with this approach (7).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma

Laurie

Gray

Zhang

et al. 2005

Clinical Cancer Research

117

131

View full text Add to dashboard Cite

Chemotherapy combined with laser therapy and cryotherapy has improved the ocular salvage rate for children with bilateral retinoblastoma. However, children with late-stage disease often experience recurrence shortly after treatment. To improve the vision salvage rate in advanced bilateral retinoblastoma, we have developed and characterized two new rodent models of retinoblastoma for screening chemotherapeutic drug combinations. The first model is an orthotopic xenograft model in which green fluorescent protein^or luciferase-labeled human retinoblastoma cells are injected into the eyes of newborn rats.The second model uses a replication-incompetent retrovirus (LIA-E E1A ) encoding the E1A oncogene. Clonal, focal tumors arise from mouse retinal progenitor cells when LIA-E E1A is injected into the eyes of newborn p53 À/À mice. Using these two models combined with pharmacokinetic studies and cell culture experiments, we have tested the efficacy of topotecan combined with carboplatin and of topotecan combined with vincristine for the treatment of retinoblastoma. The combination of topotecan and carboplatin most effectively halted retinoblastoma progression in our rodent models and was superior to the current triple drug therapy using vincristine, carboplatin, and etoposide.Vincristine had the lowest LC 50 in culture but did not reduce tumor growth in our preclinical retinoblastoma models. Taken together, these data suggest that topotecan may be a suitable replacement for etoposide in combination chemotherapy for the treatment of retinoblastoma.

show abstract

“…Chemotherapeutic agents such as carboplatin and etoposide, have been shown to effectively reduce the volume of intraocular tumours in children affected by retinoblastoma [74,75]. However, the toxicity of systemic chemotherapy, still represents an issue which deserves further investigation [76,77], particularly when genomic instability is involved, as in retinoblastoma [6,7].…”

Section: Current Chemotherapy For Retinoblastoma and High Doses Of VImentioning

confidence: 99%

High Doses of Ascorbate (Vitamin C): A New Frontier in the Treatment of Intraocular Cancer

Milardi¹

2016

AOVS

View full text Add to dashboard Cite

Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin

Cited by 162 publications

References 47 publications

Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy

Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy

Topotecan Combination Chemotherapy in Two New Rodent Models of Retinoblastoma

High Doses of Ascorbate (Vitamin C): A New Frontier in the Treatment of Intraocular Cancer

Contact Info

Product

Resources

About